Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Narlumosbart (JMT103) in Giant Cell Tumor of Bone
NCT05813665Phase 3Not yet recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of narlumosbart in Giant Cell Tumor of Bone (GCTB), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
narlumosbart
03
Conditions
Giant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on NCT05813665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813665.